Compile Data Set for Download or QSAR
Report error Found 314 Enz. Inhib. hit(s) with all data for entry = 10229
TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521554(US11149054, Compound 1839)
Affinity DataEC50:  295nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521554(US11149054, Compound 1839)
Affinity DataEC50:  148nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521558(US11149054, Compound 1)
Affinity DataEC50:  145nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521558(US11149054, Compound 1)
Affinity DataEC50:  70.9nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521559(US11149054, Compound 2)
Affinity DataEC50:  163nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521559(US11149054, Compound 2)
Affinity DataEC50:  147nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521560(US11149054, Compound 2A)
Affinity DataEC50:  158nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521560(US11149054, Compound 2A)
Affinity DataEC50:  339nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521561(US11149054, Compound 2B)
Affinity DataEC50:  131nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521561(US11149054, Compound 2B)
Affinity DataEC50:  143nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521562(US11149054, Compound 10)
Affinity DataEC50:  125nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521562(US11149054, Compound 10)
Affinity DataEC50:  102nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521563(US11149054, Compound 1-A)
Affinity DataEC50:  109nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521563(US11149054, Compound 1-A)
Affinity DataEC50:  81.2nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521564(US11149054, Compound 1-B)
Affinity DataEC50:  31.6nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521564(US11149054, Compound 1-B)
Affinity DataEC50:  33.6nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521565(US11149054, Compound 7)
Affinity DataEC50:  300nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521565(US11149054, Compound 7)
Affinity DataEC50:  287nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521566(US11149054, Compound 9)
Affinity DataEC50:  317nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521566(US11149054, Compound 9)
Affinity DataEC50:  234nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521567(US11149054, Compound 3)
Affinity DataEC50:  185nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521567(US11149054, Compound 3)
Affinity DataEC50:  338nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521568(US11149054, Compound 1967)
Affinity DataEC50:  171nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521568(US11149054, Compound 1967)
Affinity DataEC50:  113nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521569(US11149054, Compound 7-B)
Affinity DataEC50:  347nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521569(US11149054, Compound 7-B)
Affinity DataEC50:  306nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521570(US11149054, Compound 7-A)
Affinity DataEC50:  248nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521570(US11149054, Compound 7-A)
Affinity DataEC50:  187nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521571(US11149054, Compound 8)
Affinity DataEC50:  446nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521571(US11149054, Compound 8)
Affinity DataEC50:  372nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521572(US11149054, Compound 4)
Affinity DataEC50:  201nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521572(US11149054, Compound 4)
Affinity DataEC50:  212nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521573(US11149054, Compound 5)
Affinity DataEC50:  182nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521573(US11149054, Compound 5)
Affinity DataEC50:  260nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521574(US11149054, Compound 6)
Affinity DataEC50:  248nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521574(US11149054, Compound 6)
Affinity DataEC50:  733nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521575(US11149054, Compound 11)
Affinity DataEC50:  117nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521575(US11149054, Compound 11)
Affinity DataEC50:  104nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521576(US11149054, Compound 2080)
Affinity DataEC50:  165nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521576(US11149054, Compound 2080)
Affinity DataEC50:  187nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521577(US11149054, Compound 2081)
Affinity DataEC50:  129nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521577(US11149054, Compound 2081)
Affinity DataEC50:  175nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521578(US11149054, Compound 2184)
Affinity DataEC50:  65.8nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521578(US11149054, Compound 2184)
Affinity DataEC50:  80nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521579(US11149054, Compound 2285)
Affinity DataEC50:  764nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521579(US11149054, Compound 2285)
Affinity DataEC50:  494nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521580(US11149054, Compound 2392)
Affinity DataEC50:  104nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521580(US11149054, Compound 2392)
Affinity DataEC50:  47.5nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2A(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521581(US11149054, Compound 2499)
Affinity DataEC50:  768nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

TargetGlutamate receptor ionotropic, NMDA 2B(Human)
Sage Therapeutics

US Patent
LigandPNGBDBM521581(US11149054, Compound 2499)
Affinity DataEC50:  751nMAssay Description:The whole-cell patch-clamp technique was used to investigate the effects of positive allosteric modulating activity of test compounds on GlunN1/GluN2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/13/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 314 total ) | Next | Last >>
Jump to: